Six Months of Chemotherapy Before Surgery Matches Four-Month Course in Pancreatic Cancer
The PACT-21/CASSANDRA phase 3 trial found that six months of preoperative chemotherapy produced event-free survival comparable to a four-month preoperative ...
The PACT-21/CASSANDRA phase 3 trial found that six months of preoperative chemotherapy produced event-free survival comparable to a four-month preoperative ...
A new review maps the fast-moving landscape of next-generation KRAS inhibitors, degraders, and combination strategies now advancing beyond the first ...
The phase 1 GlutaPanc trial shows that l-glutamine can be safely combined with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ...
A new perspective argues that radiation must be redesigned as an immunological platform to finally unlock the potential of combined ...
A new computational platform reveals how collagen architecture and myeloid cells cooperate to trap therapeutic T cells in pancreatic tumors, ...
Pancreatic cancer has long been one of medicine's most stubborn adversaries, a disease so aggressive and so difficult to detect ...
Pancreatic cancer has earned its grim reputation the hard way. Fewer than one in eight patients survives five years beyond ...
Pancreatic cancer may gain its most dangerous advantages not from a single genetic alteration, but from a molecular partnership that ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine